05 October 2021 | News
New excipient combinations help overcome manufacturing and formulation challenges of highly concentrated protein solutions by viscosity reduction
Photo Credit: Merck
The Life Science business of Merck has launched a new Viscosity Reduction Excipient Platform to reduce the viscosity and help overcome manufacturing and formulation challenges associated with highly concentrated protein solutions.
The core of the new technology platform is the combination of two new excipients, one amino acid with one anionic component. The use of excipient combinations provides the following synergies:
For protein-based therapeutics, such as monoclonal antibodies (mAbs) or plasma-derived proteins, subcutaneous administration is the preferred route of administration as it improves patient compliance. Such formulations often require highly concentrated protein formulations, however, to meet intended dosing regimens. Highly concentrated protein solutions tend to exhibit elevated viscosities, which presents a challenge in the manufacturing process and final formulation.
The synergistic effects of the excipient combinations in the Viscosity Reduction Platform deliver several advantages for formulation including:
All the excipient candidates have been previously used individually in approved drug products for humans via parenteral administration, for example as active ingredients in parenteral nutrition or as pH adjusters. The excipients will be subsequently made available in Emprove® Expert quality, supporting the described new excipient application.